Hutchison China Meditech Limited Results of Extraordinary General Meeting (4910A)
29 Mai 2019 - 1:06PM
UK Regulatory
TIDMHCM
RNS Number : 4910A
Hutchison China Meditech Limited
29 May 2019
Results of Extraordinary General Meeting
London: Wednesday, May 29, 2019: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that the
ordinary resolution and special resolution put to its Extraordinary
General Meeting ("EGM") held on May 29, 2019 were duly passed. The
poll results of the resolutions were as follows:
Number of Votes (%)*
Resolutions For Against Withheld(#)
To subdivide each ordinary
share of US$1.00 into
10 ordinary shares of
1 Ordinary Resolution: US$0.10 each. 60,074,349 1,334 570
(99.99778%) (0.00222%)
Conditional upon the listing
on The Stock Exchange
of Hong Kong Limited,
adopt a new memorandum
of association and articles
2 Special Resolution: of association of Chi-Med. 59,689,872 385,859 522
(99.35771%) (0.64229%)
* Percentages rounded to 5 decimal places
(#) A vote withheld is not a vote in law and is not counted in
the calculation of the proportion of the votes for and against a
resolution.
As at the date of the EGM, the number of Chi-Med shares
entitling the holders to attend and vote on all the resolutions was
66,657,745.
Following the passing of Resolution 1, Chi-Med confirms that
each of Chi-Med's ordinary shares of US$1.00 each ("Existing
Ordinary Shares") will be subdivided into 10 new ordinary shares of
US$0.10 each ("Subdivision") with effect on May 30, 2019. Trading
on AIM for the Existing Ordinary Shares (under ISIN KYG4672N1016)
will cease at 4:30 p.m. today and the trading in the new ordinary
shares of US$0.10 each ("New Ordinary Shares") will commence at
8:00 a.m. on May 30, 2019 under new ISIN KYG4672N1198. Application
has been made to the London Stock Exchange for the 666,657,450 New
Ordinary Shares to be admitted to the AIM market operated by the
London Stock Exchange with effect at 8:00 a.m. on May 30, 2019.
Concurrent with the Subdivision, the American Depositary Share
("ADS") ratio will be changed from 1 ADS representing one-half of
an Existing Ordinary Share to 1 ADS representing 5 New Ordinary
Shares with effect from 8:00 a.m. on May 30, 2019.
Shareholders should multiply their Existing Ordinary Shares by
ten to determine their number of New Ordinary Shares immediately
following the Subdivision.
Immediately following the Subdivision, the issued share capital
of Chi-Med will consist of 666,657,450 New Ordinary Shares, with
each share carrying one right to vote and with no shares held in
treasury. This figure of 666,657,450 may be used by shareholders as
the denominator for the calculations by which they could determine
if they are required to notify their interest in, or a change to
their interest in, Chi-Med under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules. For illustrative
purposes only, the 666,657,450 New Ordinary Shares would be
equivalent to 666,657,450 depositary interests (each equating to
one New Ordinary Share) which are traded on AIM or, if the
depositary interests were converted in their entirety, equivalent
to 133,331,490 ADSs (each equating to five New Ordinary Shares)
which are traded on the NASDAQ Global Select Market.
All of the times referred to in this announcement are to London
time unless otherwise stated.
About Chi-Med
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical
company which researches, develops, manufactures and markets
pharmaceutical products. Its Innovation Platform, Hutchison
MediPharma, has about 420 scientists and staff focusing on
discovering, developing and commercializing targeted therapeutics
and immunotherapies in oncology and autoimmune diseases. It has a
portfolio of eight cancer drug candidates currently in clinical
studies around the world. Chi-Med's Commercial Platform
manufactures, markets, and distributes prescription drugs and
consumer health products, covering an extensive network of
hospitals across China.
Dual-listed on the AIM market of the London Stock Exchange and
the Nasdaq Global Select Market, Chi-Med is headquartered in Hong
Kong and majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200
Annie Cheng, Vice President, Corporate Finance & Development +1 (973) 567 3786
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
jlo@brunswickgroup.com
- Zhou Yi, Brunswick +852 9783 6894 (Mobile)
yzhou@brunswickgroup.com
Mainland China - Sam Shen, Edelman +86 136 7179 1029 (Mobile)
sam.shen@edelman.com
Nominated Advisor
Richard Gray / Atholl Tweedie, Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMUKRARKUAVUAR
(END) Dow Jones Newswires
May 29, 2019 07:06 ET (11:06 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024